Venrock Adviser, LLC

Position in RLMD — Relmada Therapeutics, Inc.

CIK 1615982 NEW YORK, NY

Position in RLMD

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$33,709,924

-$22,488,509 QoQ

Shares Held

4,843,380

+219.1% QoQ

Ownership

4.62%

of shares outstanding

% of Portfolio

1.26%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2020

12 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Venrock Adviser, LLC holds $2,679,121,844 across 33 Biotechnology names. RLMD ranks #21 (1.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	APGE	Apogee Therapeutics, Inc.	8,493,321	$714,882,828
2	ERAS	Erasca, Inc.	16,382,812	$265,073,898
3	ORKA	Oruka Therapeutics, Inc.	4,148,428	$203,480,393
4	SYRE	Spyre Therapeutics, Inc.	3,685,448	$185,893,997
5	KALV	KalVista Pharmaceuticals, Inc.	6,474,485	$130,331,383
6	DNTH	Dianthus Therapeutics, Inc. /DE/	1,180,000	$99,025,600
7	DMRA	Damora Therapeutics, Inc.	3,603,595	$93,333,110
8	OCUL	Ocular Therapeutix, Inc	10,346,926	$87,638,463

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$33,709,924	4,843,380	+219.1%	Shares	Sole	2026-05-15
2022-09-30	$56,198,433	1,518,056	-33.1%	Shares	Sole	2023-05-15
2022-06-30	$43,108,667	2,270,072	0.0%	Shares	Sole	2023-05-15
2022-03-31	$61,269,243	2,270,072	0.0%	Shares	Sole	2022-05-16
2021-12-31	$51,144,722	2,270,072	+63.6%	Shares	Sole	2022-02-14
2021-09-30	$36,372,141	1,387,720	0.0%	Shares	Sole	2021-11-15
2021-06-30	$44,420,917	1,387,720	+62.6%	Shares	Sole	2021-08-13
2021-03-31	$30,041,383	853,206	+27.6%	Shares	Sole	2021-05-14
2020-12-31	$21,436,870	668,440	0.0%	Shares	Sole	2021-02-12
2020-09-30	$25,146,712	668,440	0.0%	Shares	Sole	2020-11-16
2020-06-30	$29,912,690	668,440	-20.7%	Shares	Sole	2020-08-14
2020-03-31	$28,748,385	842,814	—	Shares	Sole	2020-05-15
No filing history on record for this holder in this stock.